Series A co-led by founding investor M Ventures and new lead investors Hadean Ventures, Sofinnova Partners, and 4BIO Capital with syndica ...

Actithera has secured $75.5 million in an oversubscribed Series A round to support the clinical development of its lead ...

Actithera, a radiopharmaceutical biotech pioneering precision radioligand therapies, has closed an oversubscribed Series A ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention ...

BIO investing in unique radiopharmaceutical platform company, developing radioligands with prolonged tumour retention Series A was co-led by 4BIO Capital, founding investor M Ventures, Hadean Ventures ...

A new player in radioligand therapies (RLTs), Norway and US-based Actithera, has arrived on the scene with $75.5 million in ...

Actithera’s radiopharma assets irreversibly bind to their targets, allowing for longer retention of the drug inside tumors.

Along the eastern shore of Hudson Bay in Canada’s northeastern province of Quebec, near the Inuit municipality of Inukjuak, ...

The firm will use the money to advance its lead FAP-targeting radioligand candidate into clinical development.